TargetBeta
GIPR
gastric inhibitory polypeptide receptor · Glucagon receptor family
11 programs in company-led studies act on GIPR, from 9 companies: 5 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Tirzepatiderule | Eli Lilly | phase 4 | 7220 running | GLP1R | ChEMBL |
| UBT251 | The United Laboratories International | phase 3 | 1212 running | GCGR, GLP1R | a judged reading |
| retatrutiderule | Eli Lilly | phase 3 | 3311 running | GCGR, GLP1R | ChEMBL |
| olatorepatide | Hansoh Pharmaceutical Group | phase 3 | 127 running | GLP1R | a judged reading |
| enicepatide | Hoffmann-La Roche | phase 3 | 107 running | GLP1R | a judged reading |
| VK2735rule | Viking Therapeutics | phase 3 | 85 running | GLP1R | the studies' text |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 64 running | GLP1R, NPY2R | the company's pipeline |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 54 running | GCGR, GLP1R | the company's pipeline |
| NNC0519-0130 | Novo Nordisk | phase 2 | 111 running | GLP1R | a judged reading |
| GIPR Agonist LY3537021 | Eli Lilly | phase 2 | 31 running | – | the company's pipeline |
| NA-931rule | Biomed Industries | phase 2 | 31 running | GLP1R, IGF1 | the studies' text |
Conditions their studies are in
- Obesity, 9 programs
- Diabetes Mellitus, Type 2, 8 programs
- Diabetes Mellitus, 3 programs
- Overweight, 3 programs
- Fatty Liver, 2 programs
- Non-alcoholic Fatty Liver Disease, 2 programs
- Atherosclerosis, 1 program
- Diabetes Mellitus, Type 1, 1 program
- Hidradenitis Suppurativa, 1 program
- Nausea, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026Tirzepatide · Eli Lilly · phase 4 · NCT07299084
- Nov 2026retatrutide · Eli Lilly · phase 3 · NCT06662383
- Dec 2026UBT251 · The United Laboratories International · phase 3 · NCT07785934
- Dec 2026GIPR Agonist LY3537021 · Eli Lilly · phase 2 · NCT07169851
- Dec 15, 2026BI 3034701 · Boehringer Ingelheim · phase 2 · NCT07837648
- Mar 2027HRS-4729 · Jiangsu HengRui Medicine · phase 2 · NCT07690826
- Mar 30, 2027olatorepatide · Hansoh Pharmaceutical Group · phase 3 · NCT07156500
- Apr 8, 2027enicepatide · Hoffmann-La Roche · phase 3 · NCT07626515
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.